Press Releases

Avilar Therapeutics today announced that its company leaders will participate in two upcoming industry conferences, highlighting the company’s proprietary protein degradation platform capabilities and associated opportunities to target historically intractable pathogenic proteins.

WALTHAM, Mass., August 29, 2023 – Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced that Adam Muzikant, Ph.D., the company’s Chief Business Officer, will present at the upcoming Wells Fargo Healthcare Conference in Boston at 4:30 pm ET on Wednesday, September 6, 2023. About Avilar Therapeutics Avilar Therapeutics is a biopharmaceutical company […]

New investors Sanofi Ventures, Medical Excellence Capital, and Astellas Venture Management join syndicate with founder RA Capital Management —
Funding supports advancing multiple first-in-class degrader pipeline programs for the treatment of autoimmune, neurological, and other diseases driven by pathogenic extracellular proteins

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today presented new preclinical proof-of-concept data demonstrating the degradation of extracellular proteins using its asialoglycoprotein receptor (ASGPR) targeting chimera (ATAC) platform at the Keystone Symposium on Targeted Protein Degradation being held in Vancouver, British Columbia

WALTHAM, Mass., November 1, 2022 – Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced it will present preclinical data demonstrating the degradation of extracellular proteins using its asialoglycoprotein receptor (ASGPR) targeting chimeras (ATAC) platform at the Keystone Symposium on Targeted Protein Degradation being held in Vancouver, British Columbia, November 6-8, 2022. […]

WALTHAM, Mass., October 18, 2022 – Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced that it will present new in vivo proof-of-concept data from its ATAC (ASGPR Targeting Chimera) degrader platform at two upcoming drug discovery conferences. Kevin Lumb, DPhil, VP Biology, will present at the Discovery on Target Conference being […]

WALTHAM, Mass., June 15, 2022 – Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer. Dr. Muzikant brings 18 years of business development experience creating and executing value-creating deals, from platform collaborations to commercial-stage product licenses and M&A, across a range of […]

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the formation of its Scientific Advisory Board (SAB) comprised of an esteemed group of leading scientists with expertise in protein degradation, chemistry, genetics, and drug discovery.

WALTHAM, Mass., May 3, 2022 – Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced that members of the company’s leadership team will be featured speakers on advances in the protein degradation field at two upcoming drug discovery conferences. Effie Tozzo, PhD, Chief Scientific Officer of Avilar, will deliver a keynote address […]

WALTHAM, Mass., April 19, 2022 – Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced a scientific poster presentation highlighting ATACs (ASGPR-Targeting Chimeras) at the 5th annual Protein Degradation Using PROTACs & Molecular Glues meeting being held in San Diego, April 19-20. ATACs are a new class of degraders designed to degrade […]

Avilar Therapeutics, a biopharmaceutical company focused onextracellular protein degradation, today announced that Daniel Grau, CEO and President, will present at the upcoming Guggenheim Targeted Protein Degradation Day at 2:00PM – 2:30PM on Wednesday, March 16, 2022.

Company founded and financed by RA Capital Management with vision to extend protein degradation beyond intracellular proteins. Proprietary platform enables creation of novel degraders called ATACs to treat wide range of diseases.